Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation for Patients with Hematologic Malignancies

• Published in: Journal of Huazhong University of Science and Technology. Medical sciences 2006, Vol.26 (1), p.47-49
• Main Author: 夏凌辉 方峻 游泳 郭涛 刘芳 张纯 江汇娟 邹萍
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Child; China - epidemiology; Cyclosporine - therapeutic use; Female; Follow-Up Studies; Graft vs Host Disease - prevention & control; Humans; Leukemia - therapy; Leukemia, Lymphoid - therapy; Leukemia, Myeloid, Acute - therapy; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation - adverse effects; Sepsis - epidemiology; Sepsis - etiology; 外周血; 细胞移植; 血液疾病; 造血干细胞
• ISSN: 1672-0733; 1993-1352
• DOI: 10.1007/bf02828036

To investigate the therapeutic effects and associated complications of allogeneic peripheral blood stem cell transplantation （allo-PBSCT）, 40 patients with various malignant hematopoietic diseases received allo-PBSCT. The preparative regimens were based on BUCY2 or modified BUCY2, The acute graft-versus host disease （aGVHD） was prevented by cyclosporin A and shortterm MTX regimen in all patients. Two patients from donors with one fully mismatched HLA on DRB1 locus and 4 from unrelated donor also administered Zenapox （CD25 MAb） at dosage of 1 rag/ kg every day on the day before transplantation and day 4 after transplantation. These 6 patients were also treated with mycophenolate mofetil （MMF）. Transfusion of the donor cells： The median of the transfused nucleated cells was 5.38×10^8/kg and that of the CD34^＋ cells was 7.8×10^6/kg respectively. All the patients gained hematopoietic reconstruction except one who died of infection before engraftment. Seven patients got Ⅱ°-Ⅳ° aGVHD and the incidence was 17.5 %. Fourteen patients got cGVHD and the incidence was 53.8 % in the patients who survived over 6 months. Twenty-eight patients had fever or other characteristics of infection. The median follow-up time was 13.8 months. The incidence of transplantation related mortality （TRM） was 17.5 %and 2 patients relapsed （5.0 %）. It was concluded that allo-PBSCT can reconstruct hematopoiesis quickly and is a favorable therapeutic method for leukemia.